key: cord-1056065-nwoo5ix5
authors: Sadoff, J.; Le Gars, M.; Shukarev, G.; Heerwegh, D.; Truyers, C.; de Groot, A. M.; Stoop, J.; Tete, S.; Van Damme, W.; Leroux-Roels, I.; Berghmans, P.-J.; Kimmel, M.; Van Damme, P.; De Hoon, J.; Smith, W.; Stephenson, K.; Barouch, D.; De Rosa, S.; Cohen, K.; McElrath, J.; Cormier, E.; Scheper, G.; Hendriks, J.; Struyf, F.; Douoguih, M.; Van Hoof, J.; Schuitemaker, H.
title: Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
date: 2020-09-25
journal: nan
DOI: 10.1101/2020.09.23.20199604
sha: 21d2a4fbf1954f1cd9e3c634361d867f04a2f250
doc_id: 1056065
cord_uid: nwoo5ix5

BACKGROUND The ongoing coronavirus disease (COVID)-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be controlled by an efficacious vaccine. Multiple vaccines are in development, but no efficacious vaccine is currently available. METHODS We designed a multi-center phase 1/2a randomized, double-blinded, placebo-controlled clinical study to assesses the safety, reactogenicity and immunogenicity of Ad26.COV2.S, a non-replicating adenovirus 26 based vector expressing the stabilized pre-fusion spike (S) protein of SARS-CoV-2. Ad26.COV2.S was administered at a dose level of 5x1010 or 1x1011 viral particles (vp) per vaccination, either as a single dose or as a two-dose schedule spaced by 56 days in healthy adults (18-55 years old; cohort 1a & 1b; n= 402 and healthy elderly >65 years old; cohort 3; n=394). Vaccine elicited S specific antibody levels were measured by ELISA and neutralizing titers were measured in a wild-type virus neutralization assay (wtVNA). CD4+ T-helper (Th)1 and Th2, and CD8+ immune responses were assessed by intracellular cytokine staining (ICS). RESULTS We here report interim analyses after the first dose of blinded safety data from cohorts 1a, 1b and 3 and group unblinded immunogenicity data from cohort 1a and 3. In cohorts 1 and 3 solicited local adverse events were observed in 58% and 27% of participants, respectively. Solicited systemic adverse events were reported in 64% and 36% of participants, respectively. Fevers occurred in both cohorts 1 and 3 in 19% (5% grade 3) and 4% (0% grade 3), respectively, were mostly mild or moderate, and resolved within 1 to 2 days after vaccination. The most frequent local adverse event (AE) was injection site pain and the most frequent solicited AEs were fatigue, headache and myalgia. After only a single dose, seroconversion rate in wtVNA (50% inhibitory concentration - IC50) at day 29 after immunization in cohort 1a already reached 92% with GMTs of 214 (95% CI: 177; 259) and 92% with GMTs of 243 (95% CI: 200; 295) for the 5x1010 and 1x1011vp dose levels, respectively. A similar immunogenicity profile was observed in the first 15 participants in cohort 3, where 100% seroconversion (6/6) (GMTs of 196 [95%CI: 69; 560]) and 83% seroconversion (5/6) (GMTs of 127 [95% CI: <58; 327]) were observed for the 5x1010 or 1x1011 vp dose level, respectively. Seroconversion for S antibodies as measured by ELISA (ELISA Units/mL) was observed in 99% of cohort 1a participants (GMTs of 528 [95% CI: 442; 630) and 695 (95% CI: 596; 810]), for the 5x1010 or 1x1011 vp dose level, respectively, and in 100% (6/6 for both dose levels) of cohort 3 with GMTs of 507 (95% CI: 181; 1418) and 248 (95% CI: 122; 506), respectively. On day 14 post immunization, Th1 cytokine producing S-specific CD4+ T cell responses were measured in 80% and 83% of a subset of participants in cohort 1a and 3, respectively, with no or very low Th2 responses, indicative of a Th1-skewed phenotype in both cohorts. CD8+ T cell responses were also robust in both cohort 1a and 3, for both dose levels. CONCLUSIONS The safety profile and immunogenicity after only a single dose are supportive for further clinical development of Ad26.COV2.S at a dose level of 5x1010 vp, as a potentially protective vaccine against COVID-19. Trial registration number: NCT04436276

occurred in both cohorts 1 and 3 in 19% (5% grade 3) and 4% (0% grade 3), respectively, were 23 mostly mild or moderate, and resolved within 1 to 2 days after vaccination. The most frequent 24 local adverse event (AE) was injection site pain and the most frequent solicited AEs were fatigue, 25 headache and myalgia. After only a single dose, seroconversion rate in wtVNA (50% inhibitory 26 concentration -IC50) at day 29 after immunization in cohort 1a already reached 92% with GMTs 27 of 214 (95% CI: 177; 259) and 92% with GMTs of 243 (95% CI: 200; 295) for the 5x10 10 and 28 1x10 11 vp dose levels, respectively. A similar immunogenicity profile was observed in the first 15 29 4 695 (95% CI: 596; 810]), for the 5x10 10 or 1x10 11 vp dose level, respectively, and in 100% (6/6 34 for both dose levels) of cohort 3 with GMTs of 507 (95% CI: 181; 1418) and 248 (95% CI: 122; 35 506), respectively. On day 14 post immunization, Th1 cytokine producing S-specific CD4+ T cell 36 responses were measured in 80% and 83% of a subset of participants in cohort 1a and 3, 37 respectively, with no or very low Th2 responses, indicative of a Th1-skewed phenotype in both 38

cohorts. CD8+ T cell responses were also robust in both cohort 1a and 3, for both dose levels. 39

The safety profile and immunogenicity after only a single dose are supportive for further clinical 41 development of Ad26.COV2.S at a dose level of 5x10 10 vp, as a potentially protective vaccine 42 against Trial registration number: NCT04436276 44 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

We are performing a multicenter, randomized, double-blind, placebo-controlled Phase 1/2a trial 78 to evaluate safety, reactogenicity and immunogenicity of Ad26.COV2.S at 5x10 10 or 1x10 11 vp, 79 administered intramuscularly (IM) as single-dose or two-dose schedules, 8 weeks apart, in healthy 80 adults 18-55 years of age (cohort 1a (target n=375; interim safety and immunogenicity results post 81 dose 1 reported here) and cohort 1b (target n=25; interim safety results post dose 1 reported here)) 82 and >65 years of age (cohort 3 (target n=375; interim post dose 1 safety on full cohort reported 83 here, as well as interim immunogenicity of first 15 participants that were 65-75 years of age)). 84 Enrollment of Cohort 2 will start later and will allow us to collect additional safety and 85 immunogenicity data (see Supplementary Table 1 for details on cohort 2). Overview of the clinical 86 trial design is given in Table 1 and in the flow chart in Figure 1 . with a maximum of 25 seropositive participants allowed between Cohort 1a and Cohort 3. Participants received intramuscular (IM) injections of 5x10 10 vp, 1x10 11 vp Ad26.COV2.S or 126 placebo (0.9% saline) in a 1 mL volume in the deltoid muscle at Day 1. Solicited AEs were 127 collected on diary cards for 7 days post vaccination, unsolicited AEs for 28 days after vaccination 128 and SAEs throughout the course of the study. Safety data are included up to the cut-off dates of 27 129

August 2020 (cohort 1) and 7 September 2020 (cohort 3). Baseline seropositivity was assessed by 130 local clinical assays, and blood samples for serum chemistry, hematology, and for immune 131 responses were and will be collected at several timepoints throughout the study; urine samples for 132 pregnancy testing were collected before vaccination. 133

At baseline and on Day 29, Spike (S)-specific binding antibodies were measured by ELISA. 134

Seropositivity was defined as a titer >50.3 EU/mL. SARS-CoV-2 serum neutralizing antibody 135 titers were measured in a microneutralization wtVNA using the Victoria/1/2020 SARS-CoV-2 136 strain at Public Health England (PHE). Seropositivity in the wtVNA was defined as an IC50 titer 137 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 25, 2020. . https://doi.org/10.1101/2020.09.23.20199604 doi: medRxiv preprint >58. SARS-CoV-2 S-specific T-cell responses were measured at baseline and on Day 15 by ICS 138 using two pools of S peptide pools of 15mers overlapping by 11 amino acids. A Th1 response was 139 characterized by CD4+ T cells expressing IFN-γ and/or IL-2 and not IL-4, IL-5 and/or IL13; a Th2 140 response was characterized by CD4+ T cells expressing IL-4, IL-5 and/or IL-13 and CD40L by 141 CD4+ T cells. All assays were conducted in a blinded fashion and are described in detail in the 142 Appendix. 143

This study was designed to assess safety and immunogenicity. Safety data were analyzed 146 descriptively in the full analysis set and immunogenicity data were analyzed in the per protocol 147 immunogenicity population. SARS-CoV-2 Spike (S)-binding antibody titers expressed as ELISA 148

Unit per milliliters (EU/mL), and neutralizing antibody titers in the wtVNA, expressed as the 149 reciprocal serum dilution neutralizing 50% of the test virus dose (50% inhibitory concentration 150

[IC50]), are displayed on a log10 scale and described using geometric mean titers (GMT) and 95% 151 confidence intervals (95% CIs). For both assays, seroconversion was defined as having an antibody 152 titer above the lower limit of quantification (LLOQ) post vaccination if the baseline titer was below 153 the LLOQ, or a 4-fold increase over baseline post vaccination if the baseline titer was above the 154 LLOQ. ICS responses were described as percentage of total CD4+ or CD8+ T cell population. 155

Sample positivity was determined with a one-sided Fisher's exact test comparing non-stimulated 156 versus S peptide stimulated wells. LLOQ was 0.022% and non-quantifiable values were imputed 157 to LLOQ/2. Th1/Th2 ratio was calculated if the Th1 and/or Th2 responses were positive and above 158 2xLLOQ. If the Th1 or Th2 response from a participant was not fulfilling these criteria, the 159 Th1/Th2 ratio was considered >1 if a Th2 response could not be measured and <1 if a Th1 response 160 could not be measured. 161 162 163 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 25, 2020. . https://doi.org/10.1101/2020.09.23.20199604 doi: medRxiv preprint

Screening of participants started July 13, 2020, first vaccination of cohort 1a participants (age 18-166 55) was initiated on July 22, 2020 and completed on August 4, 2020, and in cohort 1b participants 167 initiated on July 29, 2020 and completed on August 7, 2020. 575 volunteers were screened, of 168 whom 380 were enrolled in cohort 1a (377 vaccinated) and 28 were screened and 25 enrolled in 169 cohort 1b (25 vaccinated; Figure 1A ). Seven (1.7%) participants were seropositive for SARS-CoV-170 2 at screening, seropositivity rate for Ad26 will be reported later. Vaccinations of cohort 3 171 participants (age >65) were initiated on August 3, 2020 and first vaccinations were completed on 172

August 24, 2020. 660 volunteers were screened, of whom 405 were enrolled and 403 were 173 vaccinated (at the time of database extract, safety and reactogenicity data was available for 394 174 vaccinated participants; Figure 1B ). Immunogenicity results of only the first 15 participants of 175 cohort 3 were available at time of this publication. 176

Baseline characteristics were broadly comparable across groups (Table 2) . 177

Blinded safety data from cohort 1a, 1b and 3 were collected and analyzed. Solicited AEs were 180 collected on diary cards for 7 days post vaccination, unsolicited AEs for 28 days after vaccination 181 and SAEs throughout the course of the study. The study is ongoing, and the second immunization 182 of the primary regimen will not be completed at the time of this submission. To ensure the 183 participants and the investigators evaluating the participants remain blinded in this study until the 184 last dose of the primary vaccination regimen is given, the safety data are presented without group 185 unblinding in this interim report. 186

In cohorts 1a and 1b the investigator's assessment of reactogenicity is available for 402 187 participants, of whom 288 (72%) participants have reported solicited AEs (Table 3) 

AEs were reported in 235 (58%) participants -mostly grade 1/grade 2. Three participants reported 189 participants who experienced grade 1 or 2 fevers, 83% utilized antipyretics at the onset of 195 symptoms. 91% of the participants who experienced grade 3 fevers utilized antipyretics at the 196 onset of symptoms. Overall, 98 participants have reported unsolicited AEs with 12 reporting grade 197 3 AEs (Table 4) . 198

In cohort 3, at the time of database extract, investigator's assessment of reactogenicity is available 199 for 394 participants, of whom 183 (46%) participants have reported solicited AEs (Table 3) . No grade 4 AEs, solicited or unsolicited, were reported in any cohort. 209

No participant discontinued the study due to an AE. There were two SAEs: one hypotension judged 210 by the investigator to not be vaccine related because of a past history of recurrent hypotension, and 211 one participant with fever who was hospitalized overnight because of suspicion of COVID-19, wo 212 recovered within 12 hours, the fever was subsequently judged by the investigator to be vaccine 213 related. For details see supplementary material. 214

While reactogenicity was acceptable in all groups, there was a trend for higher reactogenicity with 215 the higher vaccine dose (data not shown) and with younger age. This will be reported in more 216 detail upon group unblinding of the data. 217 218 219

Immunogenicity data for this interim analysis were unblinded by dose level. Antibodies against a 221 stabilized SARS-CoV-2 full length Spike protein were measured by ELISA. In cohort 1a, 94% 222 and 98% of the participants that received the 5x10 10 and 1x10 11 vp dose, respectively, at baseline 223 had EU/mL GMTs to SARS-CoV-2 S protein below the LLOQ. By Day 29 after vaccination, 224

GMTs had increased to respectively 528 (95% CI: 442; 630) and 695 (95% CI: 596; 810), with 225 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 25, 2020. were positive for neutralizing antibodies against SARS-CoV-2, independent of vaccine dose level 246 that was given. The seroconversion rate at day 29 was 92% for both the 5x10 10 and 1x10 11 vp 247 group in cohort 1a and, 100% (6/6) and 83% (5/6) for the 5x10 10 and 1x10 11 vp group in cohort 3. 248 Importantly, in cohort 1a, a total of 82% and 94% of participants in the 5x10 10 and 1x10 11 vp 249 group, respectively, reached titers greater than 100, indicative of a robust response induced in the 250 vast majority of the participants after a single vaccination with Ad26.COV2.S. The wtVNA and 251 ELISA titers as measured in cohort 1a samples highly correlated, with a Spearman correlation of 252 0.86 (p<0.001, data not shown). Data from a pseudovirus expressing SARS-CoV-2 S protein 253 neutralization assay are pending and will be included in the full publication of our post dose 1 254 interim analysis. 255 256 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 25, 2020. for the 5x10 10 and 1x10 11 vp group, respectively, in cohort 1a, and 0.05% (95% CI: 0.02; 0.24) 279 and 0.07% (95% CI:0.02; 0.14), respectively, in cohort 3. 51% (95% CI: 39; 63) and 64% (95% 280 CI: 52; 75) of participants in cohort 1a had a positive CD8+ T cell response to S peptide stimulation 281 for the 5x10 10 and 1x10 11 vp group, respectively and 33% (95% CI: 4%; 78%) of participants of 282 both dose level groups in cohort 3 had a detectable vaccine induced CD8+ T cell response. 283 284 285 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The interim analysis of our Phase 1/2a study shows that our vaccine candidate Ad26.COV2.S has 287 an acceptable safety and reactogenicity profile and is immunogenic at both a 5x10 10 or 1x10 11 vp. 288

Although the safety data in this interim report remain blinded, the overall occurrence independent 289 of dose level of solicited systemic AEs of 64% with a 19% fever rate (5% grade 3) in adults aged 290 18 to 55 (Cohort 1a and 1b) stands in contrast to the solicited systemic AEs of 36% with a 4% 291 fever rate (0% grade 3), found in the participants ≥ 65 years of age. This finding suggests that the 292 vaccine candidate is less reactogenic in older adults. The safety profile is acceptable at any age 293

given the seriousness of the disease the vaccine can potentially protect against and the nature of 294 the pandemic, especially in the elderly which is the most vulnerable population to COVID-19. We 295 did observe a trend for higher reactogenicity with the higher vaccine dose. More details on the 296 safety and reactogenicity profile will be provided immediately upon group unblinding of the study, 297 after vaccine dosing in cohort 1a and 3 has been completed. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 25, 2020. raised a theoretical concern of VAERD. 13-15 An association between this safety concern and poor 338 neutralizing potency of humoral immunity and Th2-skewed cellular immune responses has been 339 suggested. Here we show that all Ad26.COV2.S elicited CD4+ T cell responses were Th1 skewed 340 with no or very low Th2 responses. Indeed, in all responders, the Th1/Th2 ratio was above 1, in 341 line with previous experience with our Ad26-based vaccine platform (data on file). 10 This robust 342 CD4+ Th1 response was accompanied by strong CD8+ T cell responses following vaccination. 343 against SARS.CoV.2 infection or COVID-19, the durability of protection will be important to 348 characterize. Data on the durability of the immune response elicited by a single dose of 349

Ad26.COV2.S as well as on the immune response after a second dose of Ad26.COV2.S will 350 become available from our ongoing Phase 1/2a studies (Table 1 ). In previous studies with the 351 Ad26-based Zika vaccine, durability of neutralizing antibodies after a single dose, defined as 352 seropositivity, was at least 12 months in 56% of vaccine recipients and a second dose further 353 increased this percentage. 10 Obviously, durability of immunity is not only reflected in the 354 maintenance of neutralizing antibody titers but also in the quality of vaccine priming of the 355 immune system resulting in immune memory. To this end, we will study the ability of vaccinated 356 participants in our ongoing Phase 2a study (COV2001) to mount an anamnestic response to a very 357 low dose of vaccine as a surrogate for exposure to SARS-CoV-2. 358

The interpretation of the interim analysis presented here for immunogenicity is limited by the 360 relatively small sample size in cohort 3, the short follow-up, and the demographic characteristics 361 of the study population, which may limit the generalizability of our findings. However, additional 362 data will become available soon. 363

In conclusion, our interim analysis indicates that a single dose of Ad26.COV2.S, either 5x10 10 vp 365 or 1x10 11 vp, is safe, well tolerated and highly immunogenic. Based on similar immunogenicity of 366 both dose levels, we have selected the lower dose for further clinical evaluation. In our first Phase 367 3 study that has been initiated in the US, and that will later include sites in Africa, and South and 368

Central America (Trial Number: NCT04505722), we will evaluate the efficacy of a single dose of 369 5x10 10 vp of the Ad26.COV2.S vaccine candidate. An additional Phase 3 study is planned to assess 370 the efficacy and durability of immunity of a two-dose schedule with 5x10 10 vp of the 371 Ad26.COV2.S vaccine. 372 373 374 375 376 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 25, 2020. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 25, 2020. . https://doi.org/10.1101/2020.09.23.20199604 doi: medRxiv preprint preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 25, 2020. . https://doi.org/10.1101/2020.09.23.20199604 doi: medRxiv preprint preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 25, 2020. . https://doi.org/10.1101/2020.09.23.20199604 doi: medRxiv preprint Legend to Figure 1 Participants were enrolled concurrently at Belgian and US sites. Participants 490 were randomized in parallel in a 1:1:1:1:1 ratio to one of five vaccination groups to receive one or 491 two IM injections of Ad26.COV2.S at two dose levels of either 5x10 10 vp or 1x10 11 vp, or placebo. 492

For cohort 1 and 3, in the absence of clinically significant findings 24 hours after the first 493 vaccination was administered to five sentinel participants (two per dose level and one placebo), 494 another ten participants were vaccinated across all groups. Safety data up to Day 28 were then 495 reviewed by an internal data review committee before the remaining participants were randomized. 496 497 498 499 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 25, 2020. . https://doi.org/10.1101/2020.09.23.20199604 doi: medRxiv preprint Figure 2 : Immunogenicity of Ad26.COV2.S 500 501 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 25, 2020. 

Disease outbreak news. 2020. Emergencies preparedness, response. Pneumonia 405 of unknown origin

A Novel Coronavirus from Patients with Pneumonia in 408

Safety and immunogenicity of the ChAdOx1 410 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, 411 randomised controlled trial

An mRNA Vaccine against SARS-CoV-2 414 -Preliminary Report

Single-shot Ad26 vaccine protects against 417

SARS-CoV-2 in rhesus macaques

Online ahead of print

Phase 1/2 study of COVID-19 RNA vaccine 420

Online ahead of 421 print

Ad26-vector based COVID-19 vaccine 423